沙库巴曲缬沙坦钠联合重组人脑利钠肽治疗冠心病心力衰竭的效果

Effect of Sacubattril Valsartan Sodium Combined with Recombinant Human Brain Natriuretic Peptide in the Treatment of Coronary Heart Disease with Heart Failure

目的观察冠心病心力衰竭(HF)患者采用沙库巴曲缬沙坦钠联合重组人脑利钠肽(rhBNP)治疗的效果。方法选择2021年5月—2023年5月淄博桓台圣洁医院收治的95例冠心病HF患者为研究对象,按照乱数表法随机分为对照组(n=47)和观察组(n=48)。对照组采用沙库巴曲缬沙坦钠治疗,观察组采用沙库巴曲缬沙坦钠联合rhBNP治疗。比较两组患者的临床疗效、心功能、血清学指标水平、运动耐力及不良反应发生情况。结果观察组的治疗总有效率为95.83%,高于对照组的76.60%,差异有统计学意义(P<0.05)。治疗前,两组的心指数(CI)、左室射血分数(LVEF)、每搏输出量(SV)、心输出量(CO)水平比较,组间差异无统计学意义(P>0.05);治疗4周后,观察组的LVEF、CI水平均高于对照组,SV、CO均多于对照组,组间差异有统计学意义(P<0.05)。治疗前,两组的血清心锚重复蛋白(CARP)、醛固酮(ALD)、细胞间黏附分子-1(ICAM-1)、血清线粒体偶联因子6(CF6)水平比较,组间差异无统计学意义(P>0.05);治疗4周后,观察组的CARP、ICAM-1、ALD、CF6水平均低于对照组,组间差异有统计学意义(P<0.05)。治疗前,两组的最大吸氧量(VO2max)、6 min步行距离(6MWD)水平比较,组间差异无统计学意义(P>0.05);治疗4周后,观察组的VO2max高于对照组,6MWD长于对照组,组间差异有统计学意义(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论沙库巴曲缬沙坦钠联合rhBNP治疗冠心病HF的效果显著,能有效改善患者的心功能,调节血清学指标水平,提高运动耐力,且安全性良好。

Objective To observe the effect of sacubattril valsartan sodium combined with recombinant human brain natriuretic peptide(rhBNP)in patients with coronary heart disease with heart failure(HF).Methods A total of 95 patients with coronary heart disease with HF admitted to Huantai Holy Hospital in Zibo City from May 2021 to May 2023 were selected as the research subjects,randomly divided into a control group(n=47)and an observation group(n=48)according to random number table method.The control group was treated with sakubactril valsartan sodium,and the observation group was treated with sakubactril valsartan sodium combined with rhBNP.The clinical efficacy,cardiac function,serological indexes,exercise endurance and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 95.83%,which was higher than 76.60%of the control group,the difference was statistically significant(P<0.05).Before treatment,there were no significant differences Cardiac Index(CI),left ventricular ejection fraction(LVEF),stroke volume(SV),cardiac output(CO)between the two groups(P>0.05);after 4 weeks of treatment,the levels of LVEF,CI in the observation group were higher than those in the control group,the SV and CO in the observation group were more than those in the control group,and the differences between the groups were statistically significant(P<0.05).Before treatment,there were no significant differences in serum cardiac anchor repeat protein(CARP),Aldosterone(ALD),intercellular adhesion molecule-1(ICAM-1),mitochondrial coupling factor 6(CF6)between the two groups(P>0.05);after 4 weeks of treatment,the levels of CARP,ICAM-1,ALD and CF6 in the observation group were lower than those in the control group,and the differences between the groups were statistically significant(P<0.05).Before treatment,there were no significant differences in maximum oxygen intake(VO2max),6 min walking distance(6MWD)between the two groups(P>0.05);after 4 weeks of treatment,the levels of VO2max in the observation group was higher than that in the control group,the 6MWD in the observation group were significantly longer than that in the control group,and the differences between the groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Sakubactril valsartan sodium combined with rhBNP has a significant effect in the treatment of coronary heart disease with HF,which can effectively improve the cardiac function of patients,adjust the levels of serological indicator,improve exercise endurance,and has good safety.